pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

UNCOVERseq (IDT off-target CRISPR nomination method)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
61% · fresh
Computed at
2026-08-20T10:56:07.425474+00:00
Claimed
85

Public ambition and stated capability

Reported
82

Observed practitioner reporting

Verified
74

Independently supported evidence

Gap
+11

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Track; not yet

Why
UNCOVERseq is a wet-lab/bioinformatics sequencing assay for CRISPR off-target nomination — a specialized life-sciences lab method with no direct build/buy/integrate surface for pragma.vision's AI-native commerce ecosystem; it belongs in the register as a domain signal only.
Next
No action beyond registry tracking; revisit only if a Pragma.Vision-adjacent biotech/gene-therapy platform surfaces a concrete need for CRISPR off-target risk-assessment tooling or if UNCOVERseq becomes a dependency cited by a tracked partner.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
5
Tier 1
0
Tier 2
1
Tier 3
4
Supports
3
Contradicts
1
Context
1
Latest observed
2026-08-17

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-08-17 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.